While domestic sales in the second quarter are expected to be weak for major players, Lupin is likely to outperform the pharma sector on the back of a growing chronic portfolio.Group president and......
Indian pharmaceutical companies may have units abroad as part of “distributed manufacturing” across various locations, according to industry veterans. Illustration: Uttam......
The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India. Pharma major Lupin has divested its entire stake in its Japanese subsidiary,......
Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time. Mumbai-headquartered Lupin is firming up plans to......
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally. Kyowa Pharmaceutical Industry, drug major Lupin's Japanese subsidiary, has......